TAIWAN LIPOSOME/S (NASDAQ:TLC) Given “Buy” Rating at HC Wainwright

Share on StockTwits

HC Wainwright reiterated their buy rating on shares of TAIWAN LIPOSOME/S (NASDAQ:TLC) in a report released on Monday, AnalystRatings.com reports. The firm currently has a $11.00 price target on the stock.

Several other equities analysts have also recently issued reports on TLC. Zacks Investment Research upgraded TAIWAN LIPOSOME/S from a hold rating to a buy rating and set a $5.75 price target on the stock in a research report on Friday, May 15th. ValuEngine upgraded TAIWAN LIPOSOME/S from a hold rating to a buy rating in a research note on Thursday, August 6th. Finally, Cantor Fitzgerald increased their price target on TAIWAN LIPOSOME/S from $10.00 to $12.00 and gave the stock an overweight rating in a report on Monday, June 1st.

TLC opened at $5.34 on Monday. TAIWAN LIPOSOME/S has a one year low of $2.48 and a one year high of $12.65. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.63 and a current ratio of 1.63. The stock has a market capitalization of $222.58 million, a P/E ratio of -7.74 and a beta of 1.30. The business’s 50-day simple moving average is $5.89 and its 200-day simple moving average is $5.02.

TAIWAN LIPOSOME/S (NASDAQ:TLC) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.13). The firm had revenue of $0.40 million for the quarter. TAIWAN LIPOSOME/S had a negative return on equity of 145.32% and a negative net margin of 1,514.38%. On average, equities research analysts forecast that TAIWAN LIPOSOME/S will post -0.62 EPS for the current fiscal year.


Taiwan Liposome Company, Ltd., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of nanomedicines that combine its proprietary lipid-assembled drug delivery platform with approved active pharmaceutical ingredients (APIs). Its BioSeizer lipid formulation technology enables pharmacokinetic (PK) control and local sustained release of APIs at the site of disease or injury; and NanoX targeted delivery technology enables prolonged PK profiles and enhanced distribution of liposome-encapsulated APIs at the desired site.

Recommended Story: Economic Reports

Receive News & Ratings for TAIWAN LIPOSOME/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TAIWAN LIPOSOME/S and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply